Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797635 · ClinicalTrials.gov registry record · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
A Phase 2 study of Breast Cancer and Breast Neoplasms, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 372
- Enrollment target
- 17
- Study locations
NCT06797635 is a Phase 2 study of Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 372 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 10 states.
The verdict
NCT06797635, a Phase 2 study of Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 372 participants
- Enrollment target
- 17
- Study locations
Study Summary
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Patritumab deruxtecan
- DRUG Doxorubicin hydrochloride
Study Locations (17)
Other
- Seoul National University Hospital ( Site 2400) - Seoul
- Severance Hospital, Yonsei University Health System ( Site 2402) - Seoul
- Asan Medical Center ( Site 2401) - Seoul
- Hospital Universitario Reina Sofia ( Site 1702) - Córdoba
- Taichung Veterans General Hospital ( Site 2502) - Taichung
- National Cheng Kung University Hospital ( Site 2503) - Tainan
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501) - Taipei
Texas
- Texas Oncology - DFW ( Site 8000) - Dallas
- Houston Methodist Hospital ( Site 0022) - Houston
California
- UCLA Hematology/Oncology - Parkside ( Site 0021) - Santa Monica
Illinois
- Orchard Healthcare Research Inc. ( Site 0006) - Skokie
Montana
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003) - Billings
Oregon
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003) - Tigard
Tennessee
- SCRI Oncology Partners ( Site 7000) - Nashville
Virginia
- Virginia Oncology Associates (VOA) ( Site 8001) - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06797635
The ClinicalTrials.gov registry entry for NCT06797635 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06797635 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06797635 about?
NCT06797635 is a clinical study titled "Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)". Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler...
What is the current status of trial NCT06797635?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2025-03-20. Estimated completion is 2034-12-31.
What conditions does trial NCT06797635 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT06797635?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Paclitaxel (DRUG), Patritumab deruxtecan (BIOLOGICAL), Doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06797635?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06797635 being conducted?
This trial has 17 study locations across California, Illinois, Montana, Oregon, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.